Stability study of unmodified siRNA and relevance to clinical use.
about
Progress toward in vivo use of siRNAs-IIsiRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment.First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.Differential fates of biomolecules delivered to target cells via extracellular vesicles.Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD)Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease.In vivo sustained release of siRNA from solid lipid nanoparticles.Stability, Intracellular Delivery, and Release of siRNA from Chitosan Nanoparticles Using Different Cross-Linkers.Non-Invasive Intravital Imaging of siRNA-Mediated Mutant Keratin Gene Repression in Skin.Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-conceptCurrent development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma.RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeuticssiRNA: a new approach to target neuropathic pain.Delivery of RNAi therapeutics: work in progress.Delivering the promise of small ncRNA therapeutics.RNAi Screening of the Glucose-Regulated Chaperones in Cancer with Self-Assembled siRNA Nanostructures.Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.Comparative characterization and cytotoxicity study of TAT-peptide as potential vectors for siRNA and Dicer-substrate siRNA.Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdownA novel 4-arm DNA/RNA Nanoconstruct triggering Rapid Apoptosis of Triple Negative Breast Cancer Cells within 24 hoursDiblock Copolymer Hydrophobicity Facilitates Efficient Gene Silencing and Cytocompatible Nanoparticle-Mediated siRNA Delivery to Musculoskeletal Cell Types.RNA interference-based therapy and its delivery systems.Topical delivery of TRPsiRNA-loaded solid lipid nanoparticles confer reduced pain sensation via TRPV1 silencing, in rats.Delivery of siRNA in vitro and in vivo using PEI-capped porous silicon nanoparticles to silence MRP1 and inhibit proliferation in glioblastoma.Electroporation of siRNA to Silence Gene Expression in Primary NK Cells.Enhanced light-activated RNA interference using phosphorothioate-based dsRNA precursors of siRNA.RNA interference: new mechanistic and biochemical insights with application in oral cancer therapy.Evaluation of Amino-Functional Polyester Dendrimers Based on Bis-MPA as Nonviral Vectors for siRNA DeliveryPenetration and Silencing Activity of VEGF Dicer Substrate siRNA Vectorized by Chitosan Nanoparticles in Monolayer Culture and a Solid Tumor ModelIn Vitrofor Potential Application in Tumor Therapy
P2860
Q28255877-8AE171CD-2E09-4B08-9161-686846678F68Q33454280-B8B5FC26-FD99-4EEA-A531-65E8C2859209Q33630968-20B656CC-E31B-4C21-9E7D-4668EFB68447Q33730680-D8014265-BE58-4AF9-81FA-0977BCA2A927Q34043252-11056AC4-8ED6-49C0-A182-A1FDDA673336Q34209790-AEF17718-3B8F-49D7-A6A8-94686E12F086Q34610922-7E67757A-BEB0-4BCC-9EF9-F403A5739F89Q35635763-11D257C9-CAB4-4269-A34F-F8696B208942Q35661857-38CD37B6-3A71-400F-9F6E-6CF16E223203Q35689975-07C7E0C5-7823-41D4-8ED7-037BB617272EQ36674114-E624AA1C-9C0E-473A-A5D3-38DC266B855AQ36784555-4172213E-E749-413D-839D-6B7FD27F5FF2Q37690470-816DC132-076E-4154-BB86-3BB6E7CB3320Q38019046-BA6773DC-5F71-4C08-AF5A-58DC0B435432Q38051429-4C92B48A-1F0C-473D-B8A4-9893EEE832A7Q38160246-B7248DF0-155A-436F-8D83-748E74574DB5Q38226666-539A1B26-19BA-4C6E-8AA1-84BD55F0DF6CQ38743723-C6BF7839-982F-4EBC-B529-EAA61F177D68Q38811665-3375707A-D988-4DBB-BD8A-C1D9298691BFQ39107749-63EA4DF5-A43F-48D5-ADA5-B7B83177FD90Q41729089-2DDAB698-53F2-4E18-9A7E-DE3D07EADD38Q42270700-5D5AEB41-8366-42E5-ACAD-03939E52AF65Q47148640-05682942-4A05-4544-8482-4671D62AB85CQ47565462-397154A2-DD98-488E-90FB-6BC4D5395796Q47965414-FBEDFC47-BCE0-4DBF-94DD-46C1F7747347Q52719561-C29203E0-6794-4B36-9840-F7D65D1F28C7Q53101322-58663BE8-C45D-48F7-8D7C-5BDA2248054BQ53234753-702EA741-960C-4B91-BB0B-280010CE6DDDQ55360697-405B68D4-FB6B-491C-AC3D-B19830619AB2Q58693217-3BA9A5B2-B55E-4A75-BE4F-13ECEDFF42A5Q59128522-87ABD004-61C7-49E2-9846-0F173D1D7B06
P2860
Stability study of unmodified siRNA and relevance to clinical use.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Stability study of unmodified siRNA and relevance to clinical use.
@en
Stability study of unmodified siRNA and relevance to clinical use.
@nl
type
label
Stability study of unmodified siRNA and relevance to clinical use.
@en
Stability study of unmodified siRNA and relevance to clinical use.
@nl
prefLabel
Stability study of unmodified siRNA and relevance to clinical use.
@en
Stability study of unmodified siRNA and relevance to clinical use.
@nl
P2093
P2860
P356
P1433
P1476
Stability study of unmodified siRNA and relevance to clinical use.
@en
P2093
Alexander V Vlassov
Devin Leake
Emilio Gonzalez-Gonzalez
Heini Ilves
Robyn P Hickerson
Roger L Kaspar
P2860
P304
P356
10.1089/OLI.2008.0149
P577
2008-12-01T00:00:00Z